Alternative Blood Products and Clinical Needs in Transfusion Medicine
Open Access
- 8 April 2012
- journal article
- review article
- Published by Hindawi Limited in Stem Cells International
- Vol. 2012, 1-14
Abstract
The primary focus of national blood programs is the provision of a safe and adequate blood supply. This goal is dependent on regular voluntary donations and a regulatory infrastructure that establishes and enforces standards for blood safety. Progress in ex vivo expansion of blood cells from cell sources including peripheral blood, cord blood, induced pluripotent stem cells, and human embryonic stem cell lines will likely make alternative transfusion products available for clinical use in the near future. Initially, alloimmunized patients and individuals with rare blood types are most likely to benefit from alternative products. However, in developed nations voluntary blood donations are projected to be inadequate in the future as blood usage by individuals 60 years and older increases. In developing nations economic and political challenges may impede progress in attaining self-sufficiency. Under these circumstances, ex vivo generated red cells may be needed to supplement the general blood supply.Keywords
This publication has 143 references indexed in Scilit:
- Persistence of Lymphocytotoxic Antibodies in Patients in the Trial to Reduce Alloimmunization to Platelets: Implications for Using Modified Blood ProductsTransfusion Medicine Reviews, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Duration of red blood cell storage and survival of transfused patients (CME)Transfusion, 2010
- Adoptive T cell therapy of cancerCurrent Opinion in Immunology, 2010
- Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitutionNature Medicine, 2010
- The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion‐related acute lung injury risk reduction strategyTransfusion, 2009
- Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood productsHuman Immunology, 2009
- Granulocyte transfusion therapy: a new era?Current Opinion in Hematology, 2009
- Evolution of adverse changes in stored RBCsProceedings of the National Academy of Sciences, 2007
- Transfusion in sub-Saharan Africa: does a Western model fit?Journal of Clinical Pathology, 2007